Results and conclusions:
• The Group A herpesvirus CFS patients (no coinfections) returned to a near-normal to normal life (P = 0.0001). [Probability of result occuring by chance 1 in 10,000.]
- The long-term EIPS value increased (primary endpoint, P < 0.0001) with subset-directed long-term valacyclovir and/or valganciclovir therapy.
- Secondary endpoints (cardiac, immunologic, and neurocognitive abnormalities) improved or disappeared.
• Group B CFS patients (herpesvirus plus coinfections) continued to have CFS.
Source: Virus Adaptation and Treatment, May 2010;2010(2). Lerner AM, Begaj S, Fitzgerald JT, Gill K, Gill C, Edington J. Department of Medicine, William Beaumont Hospital, Royal Oak; Wayne State University School of Medicine, Detroit; Department of Medical Education, University of Michigan Medical School, Ann Arbor; Dr A Martin Lerner Chronic Fatigue Syndrome Foundation, Beverly Hills, Michigan, USA. [Email: email@example.com]
[To read ME/CFS science reporter Cort Johnson's very informative article on this research and his interview with Dr. Lerner, click here.]